Journal of Vaccine Research 2024, Vol.14, No.2, 54-64
http://medscipublisher.com/index.php/jvr

Review Article **Open Access**

Vaccination Strategies to Mitigate Antimicrobial Resistance: Global Perspectives

Tian Chen
Jilin Beodo Medical Immunization Products Co., Ltd., Jilin, 132013, Jilin, China
Corresponding email: chentian@126.com
Journal of Vaccine Research 2024, Vol.14, No.2 doi: 10.5376/jvr.2024.14.0007
Received: 12 Mar., 2024
Accepted: 15 Apr., 2024
Published: 25 Apr., 2024

Preferred citation for this article:
Chen T., 2024, Vaccination strategies to mitigate antimicrobial resistance: global perspectives, Journal of Vaccine Research, 14(2): 54-64 (doi: 10.5376/jvr.2024.14.0007)

Abstract Antimicrobial resistance (AMR) poses a significant threat to global health, leading to increased morbidity, mortality, and healthcare costs. Traditional approaches to combat AMR, such as antibiotic stewardship and the development of new antibiotic, have proven insufficient. Vaccines offer a promising alternative by preventing infections and reducing the need for antibiotics. This study explores the role of vaccination strategies in mitigating antimicrobial resistance from a global perspective, highlighting the current state of vaccine development, their impact on AMR, and the challenges and future prospects in this field. The results showed that vaccines have demonstrated substantial efficacy in reducing the incidence of infections and subsequent antibiotic use, thereby decreasing the emergence of AMR. For instance, the introduction of pneumococcal conjugate vaccines (PCV) in Ethiopia has significantly slowed the development of AMR, reducing antimicrobial treatment failures and AMR-related deaths. Existing vaccines, such as those for *Haemophilus influenzae* type B and *Streptococcus pneumoniae*, have shown impressive results in reducing antibiotic use and AMR. Furthermore, novel vaccine technologies, including virus-like particles (VLPs), offer promising avenues for future vaccine development against AMR-related pathogens. Vaccination strategies play a crucial role in the global fight against antimicrobial resistance. By preventing infections and reducing antibiotic use, vaccines can significantly mitigate the development and spread of AMR. Continued investment in vaccine research and development, along with international collaboration, is essential to harness the full potential of vaccines in combating AMR.
Keywords Antimicrobial resistance; Vaccines; Pneumococcal conjugate vaccine; Virus-like particles; Global health; Antibiotic use; Vaccine development

1 Introduction

Antimicrobial resistance (AMR) has emerged as a critical global health threat, characterized by the ability of microorganisms to withstand the effects of medications that once effectively treated infections. The misuse and overuse of antimicrobial in human medicine, agriculture, and animal husbandry have accelerated the development and spread of resistant strains, leading to increased morbidity, mortality, and healthcare costs (Jansen et al., 2018; Micoli et al., 2021; Costanzo and Roviello, 2023). The World Health Organization (WHO) has declared AMR a global emergency, necessitating urgent and coordinated action to mitigate its impact (Jansen and Anderson, 2018; Buchy et al., 2019). Traditional approaches to combat AMR, such as antimicrobial stewardship and the development of new antimicrobial, have proven insufficient on their own, highlighting the need for innovative strategies (Ozawa et al., 2021; Saeed et al., 2023).

Vaccination presents a promising and underutilized strategy in the fight against AMR. By preventing infections, vaccines reduce the need for antibiotic, thereby decreasing the selection pressure for resistant strains (Lipsitch and Siber, 2016; Jansen et al., 2018; Micoli et al., 2021). Vaccines have demonstrated significant success in reducing the incidence of diseases caused by antibiotic-resistant pathogens, such as *Haemophilus influenzae* type B (Hib) and *Streptococcus pneumoniae* (Jansen and Anderson, 2018; Ozawa et al., 2021). Moreover, vaccines can contribute to herd immunity, protecting unvaccinated individuals and further reducing the spread of resistant bacteria (Kumar, 2018; Saeed et al., 2023). The development of next-generation vaccines targeting resistant pathogens holds great potential to curb the AMR crisis (Rosini et al., 2020; Costanzo and Roviello, 2023).

This study explores the role of vaccination strategies in mitigating antimicrobial resistance (AMR) from a global perspective. By reviewing existing literature and case studies, it highlights the effectiveness of vaccines in reducing antibiotic use and preventing the spread of resistant infections. The study examines the current state of vaccine development against resistant pathogens and identifies challenges and opportunities for future research and policy implementation. This research underscores the critical importance of incorporating vaccination into global AMR action plans and provides actionable insights for stakeholders in public health, research, and policy-making.

2 Background on Antimicrobial Resistance

2.1 Mechanisms of AMR development

Antimicrobial resistance (AMR) is a significant global health threat that has been exacerbated by the misuse and overuse of antibiotics in humans, livestock, and agriculture. The development of AMR is primarily driven by the selective pressure exerted by the widespread use of antibiotics. When antibiotics are used, they kill susceptible bacteria, but resistant strains can survive and proliferate (Morrison and Zembower, 2020). This process is accelerated by inappropriate antibiotic use, such as under-dosing, over-prescribing, and using antibiotics for viral infections where they are ineffective (Jansen and Anderson, 2018; Buchy et al., 2019). Additionally, the exchange of genetic elements responsible for resistance between bacteria further propagates AMR (Kumar, 2018). The mechanisms of resistance include the production of enzymes that degrade antibiotics, alterations in bacterial cell targets, and changes in membrane permeability that prevent antibiotic entry (Buchy et al., 2019).

2.2 Current global impact of AMR

AMR poses a severe threat to global health, leading to increased mortality, prolonged hospital stays, and higher healthcare costs. It is estimated that AMR caused approximately 1.95 million deaths in 2019, with projections suggesting it could cause up to 10 million deaths annually by 2050 if not addressed (Mullins et al., 2023). The economic burden of AMR is also substantial, with increased medical expenditures and reduced productivity due to prolonged illness (Saeed et al., 2023). AMR also undermines efforts to control infectious diseases, making it a significant threat to global health security. It complicates the management of diseases like tuberculosis, malaria, and HIV/AIDS, and contributes to the resurgence of previously controlled infections.

Low- and middle-income countries are disproportionately affected by AMR due to limited access to healthcare, inadequate infection control, and the unregulated sale and misuse of antibiotics, exacerbating health disparities and hampering progress towards universal health coverage. The World Health Organization (WHO) has declared AMR a global emergency, emphasizing the need for coordinated international efforts to combat this crisis (Jansen et al., 2021; Costanzo and Roviello, 2023).

2.3 Traditional methods to combat AMR

Traditional methods to combat AMR have focused on several key strategies. Antibiotic stewardship programs aim to optimize the use of antibiotics to minimize the development of resistance by selecting the appropriate drug, dose, duration, and route of administration, while effectively treating infections (Jansen and Anderson, 2018; Buchy et al., 2019). Improving hygiene and infection control measures in healthcare settings, such as hand hygiene, disinfection and sterilization protocols, vaccination, and the use of personal protective equipment (PPE), is crucial for preventing the spread of infections in healthcare institutions and the community (Buchy et al., 2019).

Additionally, there has been a push for the development of new antibiotics, although progress has been slow due to the scientific and economic challenges associated with antibiotic research and development (Costanzo and Roviello, 2023; Mullins et al., 2023). Restricting the use of antibiotics in agriculture and livestock rearing is another important measure to reduce the overall burden of AMR (Jansen et al., 2018). While traditional methods have made some progress in addressing AMR, the rise of resistant bacterial strains continues to outpace these efforts. Novel strategies, including the use of vaccines, are urgently needed to mitigate the global impact of AMR.

3 Vaccination as a Strategy to Mitigate AMR

Antimicrobial resistance (AMR) poses a significant threat to global health, leading to increased mortality, prolonged hospital stays, and higher medical costs. Vaccination has emerged as a promising strategy to combat AMR by reducing the incidence of infections, thereby decreasing the need for antibiotics and limiting the spread of resistant strains.

3.1 Mechanisms of vaccines in reducing AMR

Vaccines alleviate AMR through multiple mechanisms. Studies have found that vaccines play a crucial role in reducing AMR. The impact of vaccines on AMR includes both direct and indirect effects. Directly, vaccines can significantly reduce the prevalence and infection of specific pathogens, thereby decreasing the use of antibiotics and the spread of resistant strains (Figure 1). Indirectly, vaccines can further prevent the spread of resistant strains through herd immunity mechanisms. For example, influenza vaccines can reduce inappropriate use of antibiotics and prevent secondary bacterial infections (Micoli et al., 2021). Additionally, vaccines can decrease the prevalence of pathogens that cause specific clinical syndromes, making it possible to use narrow-spectrum antibiotics in empirical treatments (Lipsitch and Siber, 2016).



Figure 1 Effects of vaccines on antimicrobial resistance (Adopted from Micoli et al., 2021)

Image caption: Figure a illustrates how antimicrobial-resistant strains spread among individuals and communities in the absence of vaccines, leading to antibiotic treatment failures and widespread dissemination of resistant strains. Figure b demonstrates that vaccines reduce antibiotic use and the spread of resistant strains by preventing infections and establishing herd immunity, thereby lowering the incidence of AMR. The results indicate that vaccines play a critical role in mitigating the spread of AMR (Adapted from Micoli et al., 2021)

Additionally, herd immunity extends protection to unvaccinated individuals, further reducing the spread of infections and the need for antibiotics (Lipsitch and Siber, 2016; Buchy et al., 2019; Micoli et al., 2021). Some vaccines have shown a disproportionate effect on drug-resistant lineages within target species, which can be strategically exploited in vaccine design (Lipsitch and Siber, 2016).

3.2 The successful application of vaccines

Several vaccines have demonstrated significant success in reducing AMR. As Jansen and Anderson (2018) discussed the potential of vaccines in reducing antibiotic use and antimicrobial resistance, their research found that the *Haemophilus influenzae* type B (Hib) and *Streptococcus pneumoniae* conjugate vaccines not only prevent life-threatening diseases caused by these bacteria but also significantly reduce antibiotic use and resistance. Additionally, vaccines currently in development, such as those targeting *Clostridium difficile* and *Staphylococcus aureus*, are also expected to substantially reduce antibiotic use and related resistance issues in the future (Jansen and Anderson, 2018; Qamar et al., 2021; Chen et al., 2021).

The introduction of these vaccines has led to a marked decrease in the incidence of infections caused by these pathogens, thereby reducing the need for antibiotics and limiting the spread of resistance. It is essential to increase global vaccine coverage and accelerate the development and approval process of new vaccines to address the rising challenge of antimicrobial resistance (Jansen and Anderson, 2018; Jansen et al., 2018; Jansen et al., 2021).

3.3 Emerging vaccines and technologies

Emerging vaccines and novel technologies hold great promise in the fight against AMR. Virus-like particle (VLP) vaccines, which elicit robust immune responses without containing genetic material, are being developed against key bacterial pathogens such as *Salmonella*, *Escherichia coli*, and *Clostridium difficile* (Saeed et al., 2023). Research indicates that VLP vaccines have great potential in the prevention and treatment of infectious diseases and cancer. VLP vaccines can induce high-titer and high-affinity antibody responses without the need for additional adjuvants, making them an ideal vaccine platform (Caldeira et al., 2020; Tariq et al., 2022). These vaccines offer a safer and more stable alternative to traditional vaccines and have shown promising preclinical results. Additionally, cutting-edge techniques such as RNA interference, nanomedicine, and CRISPR-based antimicrobials are under rigorous investigation for their potential to enhance vaccine efficacy and target resistant bacteria (Saeed et al., 2023).

The development of new vaccines is also being facilitated by advanced technologies like high-throughput cloning of human B cells and structure-based antigen design. These approaches enable the identification of novel protective antigens and the generation of highly specific recombinant antibodies, which can be used for passive immunization and vaccine development (Tagliabue and Rappuoli, 2018). Such innovations are crucial for addressing the complexity of resistant pathogens and overcoming technical challenges in vaccine development (Tagliabue and Rappuoli, 2018; Costanzo and Roviello, 2023).

Vaccination represents a vital strategy in mitigating AMR. By preventing infections, reducing antibiotic use, and limiting the spread of resistant strains, vaccines can play a crucial role in addressing this global health threat. Continued research and development of new vaccines and technologies are essential to fully harness the potential of vaccination in the fight against AMR.

4 Global Perspectives on Vaccination Strategies

4.1 North America

In North America, vaccination programs are well-established and cover a wide range of diseases. Vaccines such as those for *Haemophilus influenzae* type B (Hib) and Streptococcus pneumoniae (pneumococcal) have been particularly effective in reducing the incidence of these infections and, consequently, the use of antibiotics (Jansen and Anderson, 2018; Jansen et al., 2021).

The impact of these vaccination programs on antimicrobial resistance (AMR) has been significant. By reducing the number of infections, these vaccines have decreased the need for antibiotics, thereby reducing the selection pressure for resistant strains (Lipsitch and Siber, 2016; Jansen and Anderson, 2018; Buchy et al., 2019). Herd immunity further amplifies these benefits, extending protection to unvaccinated individuals and reducing the overall prevalence of resistant pathogens (Lipsitch and Siber, 2016; Micoli et al., 2021).

Despite these successes, challenges remain. Vaccine coverage is not uniform across all regions and populations, leading to pockets of lower immunity and higher antibiotic use. Future directions include increasing vaccine coverage, developing new vaccines for resistant pathogens, and integrating vaccination strategies with other AMR mitigation efforts (Jansen et al., 2018; Tagliabue and Rappuoli, 2018; Costanzo and Roviello, 2023).

4.2 Europe

Europe has implemented comprehensive vaccination strategies and policies aimed at reducing the burden of infectious diseases and AMR. The European Union and individual countries have prioritized the development and deployment of vaccines as part of their AMR action plans (Tagliabue and Rappuoli, 2018; Jansen et al., 2021). Vaccination has played a crucial role in reducing AMR in Europe. For instance, the introduction of pneumococcal vaccines has led to a significant decline in antibiotic-resistant Streptococcus pneumoniae infections. Similar trends have been observed with other vaccines, contributing to a reduction in antibiotic use and resistance (Jansen and Anderson, 2018; Jansen et al., 2021).

Barriers to the effective implementation of vaccination programs in Europe include vaccine hesitancy, logistical challenges, and disparities in healthcare access. Solutions involve public education campaigns to increase vaccine acceptance, improved vaccine distribution networks, and policies to ensure equitable access to vaccines (Jansen et al., 2018; Kumar, 2018; Costanzo and Roviello, 2023).

4.3 Asia

Vaccination programs in Asia vary widely between countries, with some nations having robust programs and others facing significant challenges. Efforts are ongoing to expand vaccine coverage and introduce new vaccines to combat AMR (Micoli et al., 2021; Costanzo and Roviello, 2023). The effectiveness of vaccination programs in Asia has been mixed. While some countries have seen substantial reductions in AMR due to successful vaccination campaigns, others struggle with low coverage and high rates of antibiotic misuse. Challenges include limited healthcare infrastructure, vaccine accessibility, and public awareness (Jansen et al., 2018; Tagliabue and Rappuoli, 2018; Buchy et al., 2019). Future directions for vaccination strategies in Asia include increasing investment in healthcare infrastructure, enhancing public education on the benefits of vaccination, and developing region-specific vaccines to address local AMR challenges. International collaborations and support from global health organizations will be crucial in these efforts (Lipsitch and Siber, 2016; Micoli et al., 2021; Saeed et al., 2023).

By examining these global perspectives, it becomes clear that while vaccination strategies have made significant strides in mitigating AMR, ongoing efforts and innovations are essential to overcome existing challenges and further reduce the global burden of antimicrobial resistance.

5 Case Studies

5.1 Application of pneumococcal vaccines in mitigating antimicrobial resistance

Vaccines can reduce antibiotic use and thus mitigate the problem of resistance through multiple pathways, including preventing infections by specific pathogens, reducing the severity of symptoms, selecting specific subtypes, and reducing cross-infections (Jit and Cooper, 2020; Ruban and Struch, 2021). For example, pneumococcal vaccines have shown significant potential in reducing antimicrobial resistance (AMR). Andrejko et al. (2021) found that the implementation of pneumococcal conjugate vaccines (PCVs) significantly reduced the resistance of *Streptococcus pneumoniae* to first-line antibiotics such as penicillin, sulfamethoxazole-trimethoprim, and third-generation cephalosporins. The data show that within ten years after vaccine implementation, penicillin non-susceptibility in *Streptococcus pneumoniae* decreased by 11.75%, sulfamethoxazole-trimethoprim by 9.77%, and third-generation cephalosporins by 7.5% (Figure 2). The study also pointed out that the phenomenon of replacement by vaccine-targeted serotypes led to lower resistance levels in non-vaccine serotypes, contributing to an overall reduction in resistance (Andrejko et al., 2021). Additionally, the broad economic value of pneumococcal vaccines in controlling AMR has been confirmed, highlighting their importance in public health strategies (Htar et al., 2019; Micoli et al., 2021).



Figure 2 Changes in susceptibility to various drug classes, among all isolates (A-E) and by PCV inclusion (F-G) over a 10-year period after PCV implementation (Adopted from Andrejkod et al., 2021)

Image caption: The figure shows the changes in non-susceptibility and resistance of pneumococcal isolates to various antibiotics (penicillin, macrolides, sulfamethoxazole-trimethoprim, third-generation cephalosporins, and tetracycline (A-E)) in different regions 10 years after the implementation of PCVs. The data indicate significant reductions in resistance to penicillin, sulfamethoxazole-trimethoprim, and third-generation cephalosporins, especially among the serotypes included in the vaccine (F-G). Changes in resistance to macrolides and tetracycline are less pronounced, but the overall trend is still downward. These results demonstrate the effectiveness of PCVs in reducing resistance to multiple antibiotics, thereby alleviating the pressure on antibiotic treatments (Adapted from Andrejkod et al., 2021)

5.2 Role of Hib vaccines in combating AMR

The influenza vaccine plays a crucial role in reducing antibiotic use and addressing antibiotic resistance (AMR). Studies have shown that influenza vaccination can significantly reduce the risk of bacterial co-infections, which often complicate influenza illness and necessitate antibiotic prescriptions (Villegas et al., 2021). For instance, the Hib (*Haemophilus influenzae* type B) vaccine achieves this goal by effectively reducing the need for antibiotics. Widespread Hib vaccination has significantly lowered the incidence of Hib-related diseases, directly leading to a reduction in antibiotic use, thereby limiting the emergence and spread of resistant bacterial strains.

In areas with high vaccine coverage, the incidence of Hib-related diseases has significantly decreased, resulting in a marked reduction in antibiotic prescriptions. This not only reduces the need for individual antibiotic treatments but also lowers the risk of spreading resistant strains within the community through herd immunity effects. For example, studies by Esposito and Principi (2018) indicate that following the implementation of Hib vaccination programs, the incidence of Hib-related diseases such as otitis media and meningitis in children significantly decreased, reducing reliance on antibiotics. It has been found that the widespread use of the Hib vaccine is effective not only in developed countries but also shows significant benefits in developing countries. These regions, where sanitary conditions are relatively poor and infection risks are higher, have seen substantial improvements in public health and reductions in the burden of Hib-related diseases and excessive antibiotic use with the introduction of the vaccine (Jit and Cooper, 2020). Jansen et al. (2021) further emphasize the global public health impact of the Hib vaccine. Studies show that as Hib vaccination rates increase, the global incidence of Hib-related diseases significantly declines, leading to a corresponding reduction in antibiotic use, effectively curbing the spread of antibiotic resistance.

In summary, vaccination strategies targeting infections such as pneumococcal and influenza have shown significant benefits in reducing antimicrobial resistance. These vaccines not only prevent infections but also decrease the demand for antibiotics, thereby reducing the selection pressure for resistant strains. Implementing and expanding vaccination programs globally is crucial to maximize these benefits and address the growing threat of antimicrobial resistance (AMR).

6 Economic Impact of Vaccination in Reducing AMR

6.1 Cost-effectiveness of vaccines

Vaccination has been shown to be a cost-effective strategy in reducing antimicrobial resistance (AMR). For instance, the introduction of the pneumococcal conjugate vaccine (PCV) in Ethiopia has significantly slowed the development of AMR, resulting in substantial economic savings. Between 2011 and 2017, PCV vaccination averted approximately 718,100 antibiotic treatment failures and 9,520 AMR-related deaths, leading to savings of $32.7 million (Ozawa et al., 2021). Maintaining current PCV immunization coverage is projected to contribute an additional $7.67 million in annual AMR cost savings over five years, with potential savings increasing to $11.43 million if coverage is expanded to 85% by 2022 (Ozawa et al., 2021). This demonstrates the cost-effectiveness of vaccines in mitigating AMR by reducing the need for antibiotic treatments and associated healthcare costs.

6.2 Healthcare savings

Vaccination not only reduces the incidence of diseases but also leads to significant healthcare savings by decreasing the need for antibiotic use and preventing antibiotic-resistant infections. For example, influenza vaccination can reduce the number of bacterial superimposed infections that complicate influenza, thereby reducing antibiotic prescriptions and associated healthcare costs (Esposito and Principi, 2018). Additionally, vaccines like those for *Haemophilus influenzae* type B and *Streptococcus pneumoniae* have proven effective in reducing unwarranted antibiotic consumption and promoting herd immunity, further contributing to healthcare savings (Jansen et al., 2021). These reductions in antibiotic use and resistance translate into fewer hospital admissions and lower healthcare expenditures, highlighting the economic benefits of vaccination programs.

6.3 Broader economic implications

The broader economic implications of vaccination in reducing AMR extend beyond direct healthcare savings. By preventing infections and reducing the spread of resistant pathogens, vaccines contribute to overall public health and economic stability. The reduction in disease burden and antibiotic use can lead to increased productivity and reduced absenteeism, benefiting the economy at large (Lipsitch and Siber, 2016; Buchy et al., 2019). Furthermore, the development and implementation of vaccines can stimulate economic growth by creating jobs in the healthcare and pharmaceutical sectors and reducing the long-term economic impact of AMR (Dadgostar, 2019). International collaborations and investments in vaccine research and development are crucial for maximizing these broader economic benefits and effectively combating AMR on a global scale (Kumar, 2018; Costanzo and Roviello, 2023).

Vaccination strategies play a critical role in reducing AMR and offer substantial economic benefits through cost-effectiveness, healthcare savings, and broader economic implications. The continued support and expansion of vaccination programs are essential for mitigating the global threat of AMR and ensuring sustainable economic growth.

7 Challenges and Barriers to Effective Vaccination

7.1 Vaccine Hesitancy and Misinformation

Vaccine hesitancy, driven by misinformation and distrust in vaccines, poses a significant barrier to achieving high vaccination coverage. Misinformation about vaccine safety and efficacy can spread rapidly through social media and other platforms, leading to public reluctance to accept vaccines. This hesitancy undermines efforts to control antimicrobial resistance (AMR) by reducing the overall immunity in the population, thereby allowing resistant pathogens to persist and spread (Micoli et al., 2021; Alghamdi, 2021; Brazzoli et al., 2023).

7.2 Financial and Logistical Barriers

The development and distribution of vaccines face substantial financial and logistical challenges. The high costs associated with research and development, extensive pre- and post-licensure studies, and the need for cold chain logistics to maintain vaccine efficacy are significant hurdles. These barriers are particularly pronounced in low- and middle-income countries, where resources are limited, and healthcare infrastructure may be inadequate to support widespread vaccination programs (Lipsitch and Siber, 2016; Siles et al., 2020; Talat and Khan, 2021). Additionally, the financial constraints can delay the introduction of new vaccines, further exacerbating the AMR problem (Talat and Khan, 2021).

7.3 Policy and Regulatory Hurdles

Policy and regulatory hurdles also impede the effective deployment of vaccines. The process of regulatory approval for new vaccines is often lengthy and complex, involving rigorous safety and efficacy evaluations. This can delay the availability of vaccines that could help mitigate AMR. Furthermore, inconsistent policies across different countries can lead to disparities in vaccine access and coverage. Harmonizing regulatory frameworks and streamlining approval processes are essential to ensure timely access to vaccines globally (Ismail et al., 2021; Micoli et al., 2021; Brazzoli et al., 2023). Additionally, the lack of coordinated global policies to prioritize and fund vaccine development against AMR pathogens remains a critical challenge (Jansen et al., 2018). By addressing these challenges, we can enhance the role of vaccines in combating antimicrobial resistance and improve global public health outcomes.

8 Future Directions and Recommendations

8.1 Innovative Vaccine Development

The development of innovative vaccines is crucial in the fight against antimicrobial resistance (AMR). Current research highlights the potential of new vaccine technologies, such as virus-like particles (VLPs), which have shown promise in eliciting robust immune responses against key bacterial pathogens implicated in AMR, including *Salmonella*, *Escherichia coli*, and *Clostridium difficile* (Saeed et al., 2023). Additionally, advancements in RNA interference, nanomedicine, and CRISPR-based antimicrobials are being explored to enhance vaccine efficacy and target drug-resistant bacteria more effectively (Saeed et al., 2023). The development of vaccines specifically targeting multidrug-resistant Gram-negative bacteria, such as *Acinetobacter baumannii*, *Klebsiella pneumoniae*, and *Pseudomonas aeruginosa*, is also a priority, given their significant burden on global health (Siles et al., 2020).

8.2 Strategies to Enhance Vaccine Coverage

Enhancing vaccine coverage is essential to maximize the impact of vaccines on reducing AMR. Increasing the coverage of existing vaccines, such as pneumococcal conjugate vaccines and live attenuated rotavirus vaccines, has been shown to significantly reduce antibiotic-treated episodes of acute respiratory infections and diarrhoea in children under five years of age in low- and middle-income countries (LMICs) (Lewnard et al., 2020). Achieving universal coverage targets for these vaccines could prevent millions of additional antibiotic-treated illnesses annually (Lewnard et al., 2020). Furthermore, expanding vaccination programs to include additional age groups and high-risk populations can further reduce the burden of AMR (Kim et al., 2022). Herd immunity, achieved through widespread vaccination, can also extend protection to unvaccinated individuals, thereby amplifying the benefits of vaccination (Lipsitch and Siber, 2016).

8.3 Policy Recommendations

To effectively combat AMR through vaccination, several policy recommendations should be considered. First, there is a need for increased investment in research and development to accelerate the creation of new vaccines targeting drug-resistant pathogens (Jansen et al., 2018). Governments and health organizations should prioritize the integration of vaccines into national and global AMR strategies, recognizing their role in reducing the need for antibiotics and preventing the spread of resistant strains (Jansen et al., 2021). Economic evaluations of vaccines should be expanded to capture their benefits in reducing AMR, which can incentivize the development and introduction of the right vaccines (Jit and Cooper, 2020). Additionally, international collaborations among health workers, researchers, and policymakers are essential to build surveillance and control strategies to combat antibiotic resistance effectively (Kumar, 2018). Finally, public health campaigns should be implemented to raise awareness about the importance of vaccination in preventing infections and reducing AMR (Micoli et al., 2021).

9 Concluding Remarks

The research papers collectively underscore the significant role that vaccines play in mitigating antimicrobial resistance (AMR). Vaccines reduce the incidence of infectious diseases, thereby decreasing the need for antibiotics and limiting the emergence and spread of resistant strains. Vaccines such as those against *Streptococcus pneumoniae* and *Haemophilus* influenzae have already demonstrated their effectiveness in reducing antibiotic use and resistance. Additionally, the development of new vaccines targeting resistant pathogens is crucial for future AMR control.

Vaccination has a profound impact on AMR by preventing infections, which reduces the need for antibiotics and consequently the selection pressure for resistant strains. Herd immunity further amplifies these benefits by protecting unvaccinated individuals within the population. Vaccines are less likely to induce resistance compared to antibiotics, making them a sustainable tool in the fight against AMR. The economic benefits of vaccination, including reduced healthcare costs and improved public health outcomes, also support their broader implementation.

To maximize the potential of vaccines in combating AMR, several actions are necessary. Governments and health organizations must prioritize the development and distribution of vaccines, especially in low- and middle-income countries where the burden of AMR is often highest. Increased investment in vaccine research and development is essential to create new vaccines targeting resistant pathogens. Public health policies should also focus on improving vaccination coverage and integrating vaccination strategies into broader AMR control programs. Furthermore, international collaboration and robust surveillance systems are crucial to monitor the impact of vaccination on AMR and to adapt strategies as needed. By implementing these measures, we can harness the full potential of vaccines to reduce the global threat of antimicrobial resistance.

Acknowledgments

The author extends sincere gratitude to the two anonymous peer reviewers for their contributions to the manuscript review process.

Conflict of Interest Disclosure

The author affirms that this research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest.

References

Alghamdi S., 2021, The role of vaccines in combating antimicrobial resistance (AMR) bacteria, Saudi J Biol Sci., 28(12): 7505-7510.
https://doi.org/10.1016/j.sjbs.2021.08.054
PMid:34867055 PMCid:PMC8626314

Andrejko K., Ratnasiri B., Hausdorff W., Laxminarayan R., and Lewnard J., 2021, Antimicrobial resistance in paediatric Streptococcus pneumoniae isolates amid global implementation of pneumococcal conjugate vaccines: a systematic review and meta-regression analysis, The Lancet. Microbe, 2(9): 450-460.
https://doi.org/10.1016/S2666-5247(21)00064-1
PMid:34485957

Brazzoli M., Piccioli D., and Marchetti F., 2023, Challenges in development of vaccines directed toward antimicrobial resistant bacterial species, Human Vaccines and Immunotherapeutics, 19(2): 2228669.
https://doi.org/10.1080/21645515.2023.2228669
PMid:37449650 PMCid:PMC10351463

Buchy P., Aşçıoğlu S., Buisson Y., Datta S., Nissen M., Tambyah P., and Vong S., 2019, Impact of vaccines on antimicrobial resistance, Int J Infect Dis., 90: 188-196.
https://doi.org/10.1016/j.ijid.2019.10.005
PMid:31622674

Chen W., 2021, Will the mRNA vaccine platform be the panacea for the development of vaccines against antimicrobial resistant (AMR) pathogens?, Expert Review of Vaccines, 21(2):155-157.
https://doi.org/10.1080/14760584.2022.2011226
PMid:34818960

Costanzo V., and Roviello G., 2023, The potential role of vaccines in preventing antimicrobial resistance (AMR): an update and future perspectives, Vaccines, 11(2): 333.
https://doi.org/10.3390/vaccines11020333
PMid:36851210 PMCid:PMC9962013

Caldeira J., Perrine M., Pericle F., and Cavallo F., 2020, Virus-like particles as an immunogenic platform for cancer vaccines, Viruses, 12(5): 488.
https://doi.org/10.3390/v12050488
PMid:32349216 PMCid:PMC7291217

Dadgostar P., 2019, Antimicrobial resistance: implications and costs, Infection and Drug Resistance, 12: 3903-3910. https://doi.org/10.2147/IDR.S234610
https://doi.org/10.2147/IDR.S234610
PMid:31908502 PMCid:PMC6929930

Esposito S., and Principi N., 2018, Influenza vaccination and prevention of antimicrobial resistance, Expert Review of Vaccines, 17: 881-888.
https://doi.org/10.1080/14760584.2018.1525298
PMid:30259755

Htar M., Biggelaar A., Sings H., Ferreira G., Moffatt M., Hall-Murray C., Verstraeten T., Gessner B., Schmitt H., and Jodar L., 2019, The impact of routine childhood immunization with higher-valent pneumococcal conjugate vaccines on antimicrobial-resistant pneumococcal diseases and carriage: a systematic literature review, Expert Review of Vaccines, 18: 1069 - 1089.
https://doi.org/10.1080/14760584.2019.1676155
PMid:31585049

Ismail S., Shahid F., Khan A., Bhatti S., Ahmad S., Naz A., Almatroudi A., and Qamar M., 2021, Pan-vaccinomics approach towards a universal vaccine candidate against WHO priority pathogens to address growing global antibiotic resistance, Computers in biology and medicine, 136: 104705 .
https://doi.org/10.1016/j.compbiomed.2021.104705
PMid:34340127

Jansen K., and Anderson A., 2018, The role of vaccines in fighting antimicrobial resistance (AMR), Human Vaccines and Immunotherapeutics, 14: 2142 - 2149.
https://doi.org/10.1080/21645515.2018.1476814
PMid:29787323 PMCid:PMC6183139

Jansen K., Gruber W., Simon R., Wassil J., and Anderson A., 2021, The impact of human vaccines on bacterial antimicrobial resistance, A review, Environmental Chemistry Letters, 19(6): 4031-4062.
https://doi.org/10.1007/s10311-021-01274-z
PMid:34602924 PMCid:PMC8479502

Jansen K., Knirsch C., and Anderson A., 2018, The role of vaccines in preventing bacterial antimicrobial resistance, Nature Medicine, 24(1): 10-19.
https://doi.org/10.1038/nm.4465
PMid:29315295

Jit M., and Cooper B., 2020, The role of vaccines in combating antimicrobial resistance, European Journal of Public Health, 8: 181-206.
https://doi.org/10.1017/9781108864121.009

Kim C., Holm M., Frost I., Hasso-Agopsowicz M., and Abbas K., 2022, Global and regional burden of attributable and associated bacterial antimicrobial resistance avertable by vaccination: modelling study, BMJ Global Health, 8(7):e011341.
https://doi.org/10.1136/bmjgh-2022-011341
PMid:37414432 PMCid:PMC10335446

Kumar S., 2018, Reduction in antimicrobial resistance by the way of extensive vaccination, Human Vaccines and Immunotherapeutics, 14(12): 2955-2956.
https://doi.org/10.1080/21645515.2018.1506679
PMid:30060701 PMCid:PMC6343609

Lewnard J., Lo N., Arinaminpathy N., Frost I., and Laxminarayan R., 2020, Childhood vaccines and antibiotic use in low- and middle-income countries, Nature, 581(7806): 94-99.
https://doi.org/10.1038/s41586-020-2238-4
PMid:32376956 PMCid:PMC7332418

Lipsitch M., and Siber G., 2016, How can vaccines contribute to solving the antimicrobial resistance problem?, mBio, 7(3): e00428.
https://doi.org/10.1128/mBio.00428-16
PMid:27273824 PMCid:PMC4959668

Micoli F., Bagnoli F., Rappuoli R., and Serruto D., 2021, The role of vaccines in combatting antimicrobial resistance, Nature Reviews, Microbiology, 19(5): 287-302.
https://doi.org/10.1038/s41579-020-00506-3
PMid:33542518 PMCid:PMC7861009

Mullins L., Mason E., Winter K., and Sadarangani M., 2023, Vaccination is an integral strategy to combat antimicrobial resistance, PLOS Pathogens, 19(6): e1011379.
https://doi.org/10.1371/journal.ppat.1011379
PMid:37319164 PMCid:PMC10270329

Morrison L., and Zembower T, R, (2020), Antimicrobial resistance, Gastrointestinal Endoscopy Clinics, 30(4): 619-635.
https://doi.org/10.1016/j.giec.2020.06.004
PMid:32891221

Ozawa S., Chen H., Rao G., Eguale T., and Stringer A., 2021, Value of pneumococcal vaccination in controlling the development of antimicrobial resistance (AMR): case study using DREAMR in Ethiopia., Vaccine, 39(45): 6700-6711.
https://doi.org/10.1016/j.vaccine.2021.04.024
PMid:34538697

Qamar M., Ahmad S., Fatima I., Ahmad F., Shahid F., Naz A., Abbasi S., Khan A., Mirza M., Ashfaq U., and Chen L., 2021, Designing multi-epitope vaccine against Staphylococcus aureus by employing subtractive proteomics, reverse vaccinology and immuno-informatics approaches, Computers in biology and medicine, 132: 104389.
https://doi.org/10.1016/j.compbiomed.2021.104389
PMid:33866250

Rosini R., Nicchi S., Pizza M., and Rappuoli R., 2020, Vaccines against antimicrobial resistance, Frontiers in Immunology, 11: 1048.
https://doi.org/10.3389/fimmu.2020.01048
PMid:32582169 PMCid:PMC7283535

Ruban H., and Struch S., 2021, Vaccination as a solution of the issue of resistance S, pneumoniae, 20: 83-92.
https://doi.org/10.31631/2073-3046-2021-20-2-83-92

Saeed U., Insaf R., Piracha Z., Tariq M., Sohail A., Abbasi U., Rana M., Gilani S., Noor S., Noor E., Waheed Y., Wahid M., Najmi M., and Fazal I., 2023, Crisis averted: a world united against the menace of multiple drug-resistant superbugs -pioneering anti-AMR vaccines, RNA interference, nanomedicine, CRISPR-based antimicrobials, bacteriophage therapies, and clinical artificial intelligence strategies to safeguard global antimicrobial arsenal, Frontiers in Microbiology, 14: 1270018.
https://doi.org/10.3389/fmicb.2023.1270018
PMid:38098671 PMCid:PMC10720626

Siles M., Lugo A., and McConnell M., 2020, Vaccines for multidrug resistant Gram negative bacteria: lessons from the past for guiding future success., FEMS microbiology reviews, 45(3): fuaa054.
https://doi.org/10.1093/femsre/fuaa054
PMid:33289833

Tagliabue A., and Rappuoli R., 2018, Changing priorities in vaccinology: antibiotic resistance moving to the top, Frontiers in Immunology, 9: 1068.
https://doi.org/10.3389/fimmu.2018.01068
PMid:29910799 PMCid:PMC5992407

Talat A., and Khan A., 2021, Vaccines against antimicrobial resistance: a promising escape route for multidrug resistance., Pharmaceutical patent analyst, 10(2): 83-98.
https://doi.org/10.4155/ppa-2020-0022
PMid:33829866

Tariq H., Batool S., Asif S., Ali M., and Abbasi B., 2022, Virus-like particles: revolutionary platforms for developing vaccines against emerging infectious diseases, Frontiers in Microbiology, 12: 790121.
https://doi.org/10.3389/fmicb.2021.790121
PMid:35046918 PMCid:PMC8761975

Villegas G., Jauregui L., Moreno B., Nunez H., and Kannan S., 2021, Genesis of antibiotic resistance LXVIII: effective vaccination (Campaigns) decrease antibiotic consumption consequent antibiotic-resistance (AR) pandemic(ARP) - The exception that proves the rule, The FASEB Journal, 35(S1): 02202.
https://doi.org/10.1096/fasebj.2021.35.S1.02202